Thomas Ciulla, MD
Chief Medical Officer & Chief Development Officer, Clearside Biomedical
Dr. Ciulla is Chief Medical Officer and Chief Development Officer at Clearside Biomedical, where he supported approval of the first suprachoroidal therapy (Xipere). He previously served a VP role at Spark Therapeutics, where he led medical strategy to support approval and commercialization of Luxturna, which involved novel functional vision endpoints, complex genetic testing paradigms, new administration procedures at ocular gene therapy treatment centers, and unique reimbursement pathways associated with one-time orphan gene therapies. Prior to Spark Therapeutics, he served a VP role, in Clinical Strategy at Ophthotech (now Iveric Bio), where he contributed to clinical protocol and analysis plan development for the successful phase 3 trial of Zimura in Geographic Atrophy (OPH2003, now GATHER1). Previously, he was Co-Director of the retina service and tenure Associate Professor at Indiana University, the largest US medical school; he remains a volunteer Clinical Professor, as well as board member at Midwest Eye Institute. Dr. Ciulla graduated from Harvard College and UCSF Med School, followed by an internship and residency at Harvard Med School, fellowship at Tufts Med School, and an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine.